EMV Capital PLC
LSE:EMVC
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/S
Enterprise Value to Sales (EV/S) ratio compares a company`s total enterprise value to its revenue. It shows how much investors are paying for each dollar of the company`s sales, including both equity and debt.
Enterprise Value to Sales (EV/S) ratio compares a company`s total enterprise value to its revenue. It shows how much investors are paying for each dollar of the company`s sales, including both equity and debt.
Valuation Scenarios
If EV/S returns to its 3-Year Average (8.6), the stock would be worth GBX67.85 (47% upside from current price).
| Scenario | EV/S Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 5.9 | GBX46 |
0%
|
| 3-Year Average | 8.6 | GBX67.85 |
+47%
|
| 5-Year Average | 11.4 | GBX89.19 |
+94%
|
| Industry Average | 0 | GBX0.05 |
-100%
|
| Country Average | 0 | GBX0.03 |
-100%
|
Forward EV/S
Today’s price vs future revenue
| Today's Enterprise Value | Revenue | Forward EV/S | ||
|---|---|---|---|---|
|
GBX17.2m
|
/ |
Jul 2025
£2.4m
|
= |
|
|
GBX17.2m
|
/ |
Dec 2025
£2.9m
|
= |
|
|
GBX17.2m
|
/ |
Dec 2026
£3.5m
|
= |
|
Forward EV/S shows whether today’s EV/S still looks high or low once future revenue are taken into account.
Peer Comparison
| Market Cap | EV/S | P/E | ||||
|---|---|---|---|---|---|---|
| UK |
|
EMV Capital PLC
LSE:EMVC
|
12.9m GBP | 5.9 | -5.2 | |
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
167.2B USD | 15.8 | 57.7 | |
| US |
|
Abbott Laboratories
NYSE:ABT
|
161.2B USD | 3.6 | 25.9 | |
| US |
|
Stryker Corp
NYSE:SYK
|
125.8B USD | 5.3 | 37.9 | |
| IE |
|
Medtronic PLC
NYSE:MDT
|
106.4B USD | 3.5 | 22.7 | |
| US |
|
Boston Scientific Corp
NYSE:BSX
|
88.9B USD | 4.6 | 24.2 | |
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
48.5B USD | 7 | 43.4 | |
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
39.8B EUR | 2 | 18.8 | |
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
45.8B USD | 10.6 | 42.8 | |
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
42.8B USD | 2.7 | 24.1 | |
| US |
|
Resmed Inc
NYSE:RMD
|
32.3B USD | 5.7 | 21.3 |
Market Distribution
| Min | 0 |
| 30th Percentile | 0 |
| Median | 0 |
| 70th Percentile | 0 |
| Max | 3 279.7 |
Other Multiples
EMV Capital PLC
Glance View
NetScientific Plc is a deep tech and life sciences venture capital investment company. The firm identifies, invests in, and builds high-growth companies in the United Kingdom and internationally. The company employs a capital-light investment approach, making use of its balance sheet and syndicating investments through its wholly owned VC subsidiary, EMV Capital Partners Limited. The company secures a mixture of direct equity stakes and carried interest stakes in its portfolio of companies, creating a structure that can support a large portfolio. The company develops customized, proactive investment strategies for its subsidiaries and portfolio companies. The firm has a portfolio of approximately 70 companies with a focus on life sciences, industrials, robotics & artificial intelligence (AI), and sustainability. Its subsidiaries include Glycotest, Inc., and ProAxsis Limited, among others.
